Aagami is a strategic consulting and advisory firm that has worked with over 95 clients on more than 150 assignments since 2003. They offer services such as licensing, partnerships, divestments, mergers and acquisitions, market entry strategies, and fundraising support for clients in the pharmaceutical, biotech, medical device, and consumer healthcare industries globally. Aagami leverages a team with over 250 years of combined experience and a large network to help supplement clients' capabilities and save them time, effort, and costs.

1. → Realizing Possibilities, Together ← May 2021
Strategic Consulting |Global Advisory | Market Intelligence
95+
Clients
150+
Assignments
2020 Calamos Court, Suite 200, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com

2. In Summary – Aagami, Inc.
Multi-
geographic
presence
Large ‘C’
level
network
20+ deals
95+ Clients
150+
Assignments
Client
Success –
most
important
250+yrs
Global
Experience
Dr. Shridhar Andurkar
Nancy Chew
Dinesh Jain
Michael Rosen
US$ 500+MM
X-Border deals
and Investments
2
Godwyn Francis Dr. Carlos Velez
Strategic Consulting | Lifesciences

3. A life sciences consulting firm offering
For Global companies in
Aagami, Inc.
Strategic Consulting Global Advisory Market Intelligence
Pharma Biotech Medical Devices
Consumer
Healthcare
3

4. Support all stages of
licensing
(Product/IP/Tech)
from Pre-Clinical to
on the Market
Various types of
development
partnering
support
Support in Divestment,
M&A, IP, Techs,
Companies, etc.
To augment your
bandwidth in
regions you are
unable to reach.
In / Out
Licensing
Partnership / Co-
development
Divestiture/
Mergers /
Acquisition
Market Entry /
Development
Strategy
Your Needs, we Serve
Advisory support
for Funding /
Venture Capital
Funding /
Investment
4

5. Deep Experience of overcoming business and socio-cultural
differences of various countries/regions
Extensive ‘C’ level
network nurtured
for 18+ years
Global Deal making
skills, honed over
decades
Partners having combined
experience of 250+ years
Supplementing your
bandwidth to save time,
effort & cost
Aagami brings,
5

6. Samples of various successes
(More Details in Case Studies)
Co-Development Partnership for
Novel Protein Therapeutic Platform.
2 Deals Done
Management of MSDS through strategic
alliance . 85% Cost reduction achieved
<6 months
Raising Investments for development of
therapies & vaccines. Listing on OTC
Markets using reverse merger, Line of
Credit (US$ 10mn)
Technology Licensing of Dermal
Delivery Platform. 4 Deals signed
with 3 companies for 18 geographies
CONFIDENTIAL
Finding customers for Peptides API
for the Client. Partnered with 8
Companies
CONFIDENTIAL
6
Equity Investment from Large Pharma

7. 7
USA International
Aagami has completed over 150 assignments for more than 95 clients since 2003
Sample list of Clients whom we have served
Japan
India
Netherland
Australia
Ireland
NFL BioSciences
France
UK
Sweden
Germany
S. Korea
Portugal Turkey
Belgium
Israel

8. Representative Client List
8
• Hovione
• Plus Therapeutics
• Otomagnetics
• Promaxo
• O'Atari
• NFL Biosciences
• 4basecare
• LiftStop
• WRS
• Therakind
• Sarva Bio Remed
• Syngulon
• BioLineRx
• CFF
• EuBiologics
• Ethadox
• Quivive
• Mountain View
Pharma
• DS Oil International
• Arstat
• Temple Therapeutics
• Sanovas
• EOS BioSciences
• Avixgen
• SiSaf
• Biose
• Batu Biologics
• JRF Global
• Impel NeuroPharma
• V ClinBio / Cellix Bio
• EmerPharm / NH
Therapeutics
• Galen Pharma
(Almac)
• 22nd Century
• Dispersol
• SBLSL
• UniTargetingResearch
• ABL Lipids
• ArjoHuntleigh/ Getinge
• HoneyLab
• iNDx LifeCare
• Venus Remedies
• Opsona Therapeutics
• XL-protein
• Otago (Ubiquitome)
• Oncbiomune
• CreAgri
• Merus
• New Haven Pharma
• Novian
• Laktobiotics
• SOM Biotech SA
• NanoSensing
Technologies
• DesignMedix Inc
• Delmar Pharmaceuticals
• Bugbam
• Pieris AG
• AdvanGene Inc
• Toppan KK
• Affitech A/S
• MacuCLEAR
• Biotechnologies
International
• PLx - Protalix Pharma
• Phosphagenics Ltd (now
Avecho)
• Lifewave LLC
• Natren Inc
• Loyola University Chicago
• Agile Therapeutics
• ScyFIX
• BSV Biosciences
• Penwest Corporation
• Averion International
• Depomed now Assertio
Therapeutics
• Bennu Pharmaceuticals
• Great American Products
• KurveTech
• Genentech
• University of Utah
• Tranzyme
• Solvay
• Epicept Corporation
• Novadel
Pharmaceuticals
• Dow Chemicals
• Aegis Therapeutics
• Morton Grove
Pharmaceuticals
• Advanced Assymetrics
• Interhealth USA
• Focus Synthesis
• Source Management
International
• Bio Quant
• Unitech
Pharmaceuticals
• Eczacibasi
• CCDRD
• Ilsan Ilvac

9. Client Testimonials
9
Virtues include Aagami’s
attentiveness, network, and
integrity. Excellent and will
recommend to all
Aagami is the bridge that
crosses many gaps. Importantly
it does so openly and honestly.
Pleased by Aagami’s
professional and gracious work.
Delighted to recommend to
others
Other Consultants we worked
with in US and Canada do not
even stand in Aagami’s shadow
Founder and CEO of a California based Biopharma
Founder and CEO of a publicly Listed Australian
Technology Development Company
CEO of a Specialty Chemicals company based in North America CEO of Oregon, US based Biotech

10. Organize and manage
online/offline meetings for
Business discussions
Advise on structuring the deal
Support in negotiations
(most critical)
Complete
Agreement/Contract
Finalize
Broadcast EP/Teaser by email to
identified Relevant Companies
Follow-up with phone calls and
emails
Coordinate CDAs with
interested Companies
Supply further info through
emails
Organize conference calls for
clarifications
Prospect
Understand and capture
important details about your
asset/technology
Prepare ‘Elevator Pitch
(EP)/Teaser’ customized to
specific business culture
Identify relevant companies and
the right persons from our
database and resources, built
and nurtured over 18+years
Setup
Our Proven Approach
All these steps require ~80 hours of effort every month per geography
10

11. 11
Engagement Model
• This ‘brings skin in the
game’ of both parties
• After 6 months you may
choose to continue based
on progress
• One-time success fee
payment option also
available
• We get our profits only
from Success Bonus
• A team consisting Partner
level Consultant, Mid-
level Consultant, Analyst
is deployed
• Work with focus on your
success to get our bonus
Monthly Commitment Fee + Success Fee
Dedicated
Teamwork
Success bonus
Small Monthly
‘Commitment’
Fee
~80 hours/month/geography A small % of value received
by you
for at least 6 months
We can also work on a simple hourly basis with no minimums, by monthly fee or by the project.

12. Dinesh Jain
• Founder CEO, MBA
• Working since 1984
• Bio-Pharma clients –
Pieris, Phosphagenics,
Genentech, etc.
Dr. Mahendra
Shah, Ph D.
Michael
Rosen
Dr. Shridhar
Andurkar, Ph D. Nancy Chew Dr. Aman Ahuja,
M.D., F.P.M., F.R.C.A.
Godwyn Francis
• Scientific Advisor
• Chair and Associate Prof. of
Pharmaceutical sciences
• Midwestern Univ., Chicago
College of Pharmacy
• Working since 1991
• Business & Scientific
Advisor
• Managing Partner, Vivo
Capital
• Working since 1971.
Aagami Leadership Team
• Partner, MBA
• Since 1974, Managed 3
MNC Pharma, Agritech,
• US, Europe, Latin
America, Japan & Israel
• Regulatory Expert
• Working since 1979
• A serial entrepreneur,
veteran business
leader, biochemist and
Pharmacologist
• Medical, Clinical
• Pain Specialist and
Anaesthetist uses
multidisciplinary
approach
• Practicing since 1998
• Vice President
• 20+ BioPharma
• Accenture, Prudential
plc, TATA, pManifold
• Working since 2000
Dr. Carlos Velez,
Ph D. MBA
• Partner
• Working since 1998
• CMTx , Lacerta, Connexin,
Panion, Ventac , Penwest,
Frankel
12
Akshay Bavaria
• BD Manager
• Business Development
and Consulting since
2013

13. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for development of therapeutic vaccines
• Investments and partnering to further develop its
technologies and pipeline.
13
Louisiana based biotechnology company specializing in innovative cancer treatments
• Aagami scanned the global market, identified right investors/
partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies
moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse
merger with a OTC Markets listed company.
• This is enabling access to large sums of funds to develop
clinical stage programs.
• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing
pipeline and technologies

14. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnerships for Development and Commercialisation of Novel
Class of Protein Drugs
• The client wanted collaborative partners to develop novel
drugs in Oncology and Ophthalmology using their new class
of proteins - Anticalins®.
German Biotech company making differentiated Novel drugs
• Aagami identified right partners, and took them to 7
interested companies
• With focused efforts three companies moved to term sheet
level discussions. Two companies remained for final
negotiations.
• Aagami maintained its spirits and perseverance knowing
Indian ways of working; even when client was ready to give
up as per Western ways.
• Finally co-development partnership happened in next few
months with one company in Oncology and with another
company for ophthalmic therapy.
• Identifying right companies, advice on deal structure,
perseverance & commitment were the key success factors.
• Client signed co-development deals with 2 companies
in Oct and Dec 2013 respectively
• Aagami proved highly influential in negotiations for
finalization of the deals due to deep experience in
business culture nuances of India.
• The deals helped Pieris in their NASDAQ (PIRS) listing
in 2014, and also enabled higher valuation.
14

15. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Out-licensing of Transdermal Drug Delivery Technology
• To Out-License TPM® Technology and Co-Develop in clinic
products using proprietary Delivery technology and market
such products in India and possibly larger region.
15
TPM® Technology and Products Company from Australia
• Aagami scanned numerous companies and got 10 relevant
companies interested.
• Discussion with 8 companies progressed.
• Took client to India 3 times for term sheet level meetings
and deal signing.
• Facilitated entire evaluation and deal structuring process
• Aagami made sure testing and other protocols were
honoured before deal was made.
• During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.
• 4 Deals with 3 global companies
– The first deal was for diclofenac topical gel formulation with
TPM. The Indian partner not only launched their own
product but also out licensed to a major western pharma.
Expanded to 16 more geographies worldwide in 2016.
– The second alliance was for use in Skin Whitening and
under eye cream.
– Third deal – The prospect using TPM increased bio
availability as well as stability of a specific antibiotic. Then
sold off that division for $1.6B

16. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnership for Anti Microbial Resistant Anti-infective Drug
• Find a suitable US partner to take FDA approvals and
market their AMR Anti-infective drug, to exploit full
market potential
16
Research Driven Publicly listed Indian Pharma Company
• Partnership established for Canada Market
• Term sheet signed for US market
 Aagami approached numerous companies and got 5
relevant companies interested.
 Discussion with 3 companies progressed to Due Diligence
levels.
 Aagami also represented the client in various Trade Shows
like BIO, J P Morgan, BIO Europe and Biotech Showcase;
resulting in interested companies from Canada, Europe,
Japan and Israel
 Facilitated entire evaluation and deal structuring process
with prospective companies
 During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.

17. 17
Few client opportunities we are presently working on:
➢ Mountain View Pharma (MVP) and its PharmaPEG® technology, product candidates, data, & IP package
➢ Patented Docetaxel and Complex Generic Doxorubicin from PLUS Therapeutics
For Acquisition
➢ Lidocaine 10% Topical Patch; NDA submitted to US FDA Oct 2020; not a generic
➢ On the Market Pro-immunity supplement capsules of Rapid and synchronized dormancy-
broken (awakened) Kyoho grape seed endosperm from our Japanese client.
➢ Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.)
Fermentation.
For Licensing/Partnering/Co-development:

18. 18
Investment/Partnering/Licensing opportunities
1. Series A Open: Portable Point-Of-Care MRI
for Neuro Imaging and Interventions; Seed
round oversubscribed.
2. Seeking up to $5M Series A at $16M cap for
a magnetic drug device platform that delivers
minimally invasive and targeted treatment for
hard to reach targets. Use of proceeds: IND
submission, Phase 1 study. Raised over $10M
in non-dilutive grants & NIH contracts. Closed
further $2.6M.
3. Seeking US$1.5M for Drug-device to delay the
progression of Parkinson’s disease
(PD), prevent Asian Flush and Hangover.
4. Seeking US$1M for expansion of an Oncology
focused healthcare and data science
5. Seeking up to US$5M for our client’s botanical
drug candidate (NFL-101) without nicotine
for smoking cessation. It is delivered
subcutaneously, twice, one week apart. The funds
will be used to Conduct the 204-patient proof-of-
concept study in France, AU and NZ. Also to
conduct all technical and commercial actions to
prepare the launch of a second and final phase III
study, including the manufacturing of pivotal
product batches, with the aim of a possible
registration in Europe in 2024.

19. Offerings in Market Intelligence/Business Research
Competitive
Landscape
Assessments
Analysis of
Portfolio
Opportunities
identification
Price Discovery
Research
Due Diligence
IP and Regulatory
Research
Financial
Modeling, NPV
valuations
New Market Entry
strategy
Market
development
strategy
19

20. Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville, IL 60653, USA
+1-630-364-1837
Business Development
Godwyn Francis, Vice President
godwyn@aagami.com
+1 630-909-3341
www.aagami.com
20
CONTACT US